\n
\n\tBiocon Biologics (BBL) launched Hulio, a biosimilars version of Abbvie\u2019s blockbuster drug Humira, in the US, a market that is already getting crowded with several biosimilars.<\/p>\n
\n\tAnalysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL\u2019s revenues from the current $1 billion to around $1.65 billion by FY25.<\/p>\n
\n\tThe drug is indicated for Rheumatoid Arthritis, Psoriatic Arthritis, Crohn\u2019s Disease, Ankylosing Spondylitis and Ulcerative Colitis, among others.<\/p>\n
\n\tHumira is estimated to have $21-billion sales in 2022, and Abbvie has indicated that it expects 37 per cent drop in Humira sales with the onslaught of biosimilars.<\/p>\n
\n\tBBL had earlier launched the biosimilar version of Humira (adalimumab) in the EU about five years back and in Canada around two years ago.<\/p>\n
\n\tICICI Direct said, in a May note, that Hulio has maintained its market share at 18.5 per cent in Germany and about 10 per cent in France. It has a 6 per cent market share in Canada.<\/p>\n
\n\tIn the US market, analysts estimate the BBL can corner a 3-5 per cent share of the $18-billion Humira market by FY24-FY25.<\/p>\n
\n\tIIFL Securities said in a recent note that, \u201cWe expect Biologics revenue to increase from $1billion to $1.65 billion in FY25, driven by sales of $300 million, 100million and 200 million from Humira, Aspart and vaccines (respectively). Our estimates assume 3-5 per cent market share for Biocon in Humira by FY24\/25.\u201d<\/p>\n
\n\tBiocon’s Hulio comes at a 5 per cent discount to the current list price of Humira of $6,922\/carton. The biosimilar would also be available under another plan at a list price of about 85 per cent below that of Humira.<\/p>\n
\n\tAnalysts said that Biocon’s pricing is similar to Coherus, but Boehringer Ingelheim\u2019s (BI) product is the only interchangeable product so far. Interchangeability implies that the chemist can substitute a Humira prescription with a BI product.<\/p>\n
\n\tAlready, players like Amgen, Coherus Biosciences, BI and Sandoz have launched their biosimilar versions.<\/p>\n
\n\tKunal Randeria of Nuvama Research said that Boehringer’s product is the only interchangeable product so far and it expects to be the sole one for at least 12 months.<\/p>\n
\n\tAs such, Biocon\u2019s key products in the US have been gaining market share.<\/p>\n
\n\tJM Financial noted that Biocon\u2019s Semglee (insulin) market share is around 12 per cent now, while Fulphila (cancer drug) is at 14 per cent and Ogivri (gastric cancer) at 10 per cent.<\/p>\n
\n\t\u201cThe USFDA has accepted BBL\u2019s Corrective and Preventive Action (CAPA) for biosimilar Aspart and they await re-inspection. While the approval is likely in FY24, we believe that they may be delayed for CY24 formulary access. Biocon is confident of gaining market share in Hulio as it saw success in the EU market and has better drug device, citrate-free drug and likely formulary access,\u201d JM Financial said.<\/p>\n<\/div>\n
\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
Biocon Biologics (BBL) launched Hulio, a biosimilars version of Abbvie\u2019s blockbuster drug Humira, in the US, a market that is already getting crowded with several biosimilars.
Analysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL\u2019s revenues from the current $1 billion to around $1.65 billion by […]<\/p>\n","protected":false},"author":1,"featured_media":77194,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","_uag_custom_page_level_css":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[42],"tags":[51666,42910,51665,51667],"jetpack_publicize_connections":[],"class_list":{"0":"post-77193","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthfitness","8":"tag-abbvie","9":"tag-biocon-biologics","10":"tag-hulio","11":"tag-humira"},"yoast_head":"\n
Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics - v99news.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics - v99news.com\" \/>\n<meta property=\"og:description\" content=\"
Biocon Biologics (BBL) launched Hulio, a biosimilars version of Abbvie\u2019s blockbuster drug Humira, in the US, a market that is already getting crowded with several biosimilars.
Analysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL\u2019s revenues from the current $1 billion to around $1.65 billion by […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/\" \/>\n<meta property=\"og:site_name\" content=\"v99news.com\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-04T15:29:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg\" \/>\n<meta name=\"author\" content=\"vrtechllc98\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"vrtechllc98\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/\",\"url\":\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/\",\"name\":\"Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics - v99news.com\",\"isPartOf\":{\"@id\":\"https:\/\/v99news.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=%2C&ssl=1\",\"datePublished\":\"2023-07-04T15:29:21+00:00\",\"dateModified\":\"2023-07-04T15:29:21+00:00\",\"author\":{\"@id\":\"https:\/\/v99news.com\/#\/schema\/person\/6c3c29e7f831c1060637bf34a975016e\"},\"breadcrumb\":{\"@id\":\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=%2C&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=%2C&ssl=1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/v99news.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/v99news.com\/#website\",\"url\":\"https:\/\/v99news.com\/\",\"name\":\"v99news.com\",\"description\":\"The Daily Mirror, Be part of it.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/v99news.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/v99news.com\/#\/schema\/person\/6c3c29e7f831c1060637bf34a975016e\",\"name\":\"vrtechllc98\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/v99news.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b097cc19d353330d6d342a3edbda9006?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b097cc19d353330d6d342a3edbda9006?s=96&d=mm&r=g\",\"caption\":\"vrtechllc98\"},\"url\":\"https:\/\/v99news.com\/author\/vrtechllc98\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics - v99news.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/","og_locale":"en_US","og_type":"article","og_title":"Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics - v99news.com","og_description":"
Biocon Biologics (BBL) launched Hulio, a biosimilars version of Abbvie\u2019s blockbuster drug Humira, in the US, a market that is already getting crowded with several biosimilars.
Analysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL\u2019s revenues from the current $1 billion to around $1.65 billion by […]","og_url":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/","og_site_name":"v99news.com","article_published_time":"2023-07-04T15:29:21+00:00","og_image":[{"url":"https:\/\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg"}],"author":"vrtechllc98","twitter_card":"summary_large_image","twitter_image":"https:\/\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg","twitter_misc":{"Written by":"vrtechllc98","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/","url":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/","name":"Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics - v99news.com","isPartOf":{"@id":"https:\/\/v99news.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#primaryimage"},"image":{"@id":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=%2C&ssl=1","datePublished":"2023-07-04T15:29:21+00:00","dateModified":"2023-07-04T15:29:21+00:00","author":{"@id":"https:\/\/v99news.com\/#\/schema\/person\/6c3c29e7f831c1060637bf34a975016e"},"breadcrumb":{"@id":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#primaryimage","url":"https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=%2C&ssl=1","contentUrl":"https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=%2C&ssl=1"},{"@type":"BreadcrumbList","@id":"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/v99news.com\/"},{"@type":"ListItem","position":2,"name":"Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics"}]},{"@type":"WebSite","@id":"https:\/\/v99news.com\/#website","url":"https:\/\/v99news.com\/","name":"v99news.com","description":"The Daily Mirror, Be part of it.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/v99news.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/v99news.com\/#\/schema\/person\/6c3c29e7f831c1060637bf34a975016e","name":"vrtechllc98","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/v99news.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b097cc19d353330d6d342a3edbda9006?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b097cc19d353330d6d342a3edbda9006?s=96&d=mm&r=g","caption":"vrtechllc98"},"url":"https:\/\/v99news.com\/author\/vrtechllc98\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=%2C&ssl=1","uagb_featured_image_src":{"full":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=%2C&ssl=1",false,false,false],"thumbnail":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?resize=150%2C150&ssl=1",false,false,true],"medium":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=300%2C300&ssl=1",false,false,true],"medium_large":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?w=768&ssl=1",false,false,true],"large":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=1024%2C1024&ssl=1",false,false,true],"1536x1536":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=1536%2C1536&ssl=1",false,false,true],"2048x2048":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=2048%2C2048&ssl=1",false,false,true],"td_150x0":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?w=150&ssl=1",false,false,true],"td_218x150":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?resize=218%2C150&ssl=1",false,false,true],"td_300x0":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?w=300&ssl=1",false,false,true],"td_324x400":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?resize=324%2C400&ssl=1",false,false,true],"td_485x360":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?resize=485%2C360&ssl=1",false,false,true],"td_696x0":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?w=696&ssl=1",false,false,true],"td_1068x0":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?w=1068&ssl=1",false,false,true],"td_1920x0":["https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?w=1920&ssl=1",false,false,true]},"uagb_author_info":{"display_name":"vrtechllc98","author_link":"https:\/\/v99news.com\/author\/vrtechllc98\/"},"uagb_comment_info":0,"uagb_excerpt":"
Biocon Biologics (BBL) launched Hulio, a biosimilars version of Abbvie\u2019s blockbuster drug Humira, in the US, a market that is already getting crowded with several biosimilars.
Analysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL\u2019s revenues from the current $1 billion to around $1.65 billion by…","jetpack_sharing_enabled":true,"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/posts\/77193"}],"collection":[{"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/comments?post=77193"}],"version-history":[{"count":0,"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/posts\/77193\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/media\/77194"}],"wp:attachment":[{"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/media?parent=77193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/categories?post=77193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/v99news.com\/wp-json\/wp\/v2\/tags?post=77193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}